SYT17 is down-expressed in the responders vaccinated with tumor-loaded dendritic cells (DCs) than in the non-responders of indolent non-Hodgkin lymphoma (iNHL) (Fucà et al., 2021). Here, SYT17 is linked to neoplasm.